Madrigal Pharmaceuticals (MDGL) EBIT (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly EBIT of -$56.3 million for Q2 2026, down 19.29% year-over-year from -$69.8 million in Q2 2025, and up 39.27% quarter-over-quarter from -$92.7 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) EBIT (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported EBIT for 17 consecutive years, with -$56.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBIT fell 19.29% year-over-year to -$56.3 million; the TTM figure through Jun 2026 stood at -$322.6 million (down 4.13% YoY), while the FY2025 annual figure was -$300.1 million, up 39.72% from the prior year.
- EBIT rose to -$56.3 million in Q2 2026 per MDGL's latest filing, from -$92.7 million in the prior quarter.
- Across five years, EBIT topped out at -$47.2 million in Q2 2025 and bottomed at -$162.5 million in Q2 2024.
- Historically, EBIT has averaged -$90.1 million across 5 years, with a median of -$82.9 million in 2022.
- Annual changes were most pronounced in 2024 — EBIT plunged 94.08% — and 2025, when it surged 70.96%.
- Madrigal Pharmaceuticals' EBIT stood at -$85.3 million in 2022, then tumbled by 37.37% to -$117.2 million in 2023, then soared by 42.82% to -$67.0 million in 2024, then gained by 11.03% to -$59.6 million in 2025, then grew by 5.54% to -$56.3 million in 2026.
- Business Quant data shows MDGL's EBIT at -$56.3 million in Q2 2026, -$92.7 million in Q1 2026, and -$59.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | -56.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.31 Mn |
| Mar 31, 2026 | -92.72 Mn |
| Dec 31, 2025 | -59.61 Mn |
| Sep 30, 2025 | -113.98 Mn |
| Jun 30, 2025 | -47.20 Mn |
| Mar 31, 2025 | -79.31 Mn |
| Dec 31, 2024 | -67.00 Mn |
| Sep 30, 2024 | -116.30 Mn |
| Jun 30, 2024 | -162.54 Mn |
| Mar 31, 2024 | -152.04 Mn |
| Dec 31, 2023 | -117.18 Mn |
| Sep 30, 2023 | -98.53 Mn |
| Jun 30, 2023 | -86.45 Mn |
| Mar 31, 2023 | -78.34 Mn |
| Dec 31, 2022 | -85.30 Mn |
| Sep 30, 2022 | -80.41 Mn |
| Jun 30, 2022 | -70.27 Mn |
| Mar 31, 2022 | -57.59 Mn |
| Dec 31, 2021 | -64.60 Mn |
| Sep 30, 2021 | -63.16 Mn |